These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
614 related articles for article (PubMed ID: 27519561)
1. A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy. Lai FH; Ng DS; Bakthavatsalam M; Chan VC; Young AL; Luk FO; Tsang CW; Brelén ME Am J Ophthalmol; 2016 Oct; 170():91-99. PubMed ID: 27519561 [TBL] [Abstract][Full Text] [Related]
2. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Hashizume K; Mizota A; Yuzawa M Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637 [TBL] [Abstract][Full Text] [Related]
3. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol. Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630 [TBL] [Abstract][Full Text] [Related]
4. Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis). Lai TY; Wong RL; Chan WM Trans Am Ophthalmol Soc; 2015; 113():T8. PubMed ID: 26755855 [TBL] [Abstract][Full Text] [Related]
5. [Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography]. Liu Y; Li L; Xu G; Wang W Zhonghua Yan Ke Za Zhi; 2016 May; 52(5):328-34. PubMed ID: 27220704 [TBL] [Abstract][Full Text] [Related]
7. Correlation of integrity of cone outer segment tips line with retinal sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy. Fujita K; Shinoda K; Imamura Y; Matsumoto CS; Mizutani Y; Mizota A; Yuzawa M Am J Ophthalmol; 2012 Sep; 154(3):579-85. PubMed ID: 22818904 [TBL] [Abstract][Full Text] [Related]
8. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy. Nicolò M; Zoli D; Musolino M; Traverso CE Am J Ophthalmol; 2012 Mar; 153(3):474-480.e1. PubMed ID: 22019224 [TBL] [Abstract][Full Text] [Related]
9. Half-dose Versus Half-time Photodynamic Therapy for Central Serous Chorioretinopathy. Liu HY; Yang CH; Yang CM; Ho TC; Lin CP; Hsieh YT Am J Ophthalmol; 2016 Jul; 167():57-64. PubMed ID: 27084002 [TBL] [Abstract][Full Text] [Related]
10. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. Nicoló M; Eandi CM; Alovisi C; Grignolo FM; Traverso CE; Musetti D; Cardillo Piccolino F Am J Ophthalmol; 2014 May; 157(5):1033-7. PubMed ID: 24487046 [TBL] [Abstract][Full Text] [Related]
11. Angiographic and Tomographic Prognostic Factors of Chronic Central Serous Chorioretinopathy Treated with Half-Dose Photodynamic Therapy. Chung CY; Chan YY; Li KKW Ophthalmologica; 2018; 240(1):37-44. PubMed ID: 29566395 [TBL] [Abstract][Full Text] [Related]
12. Photodynamic therapy for steroid-associated central serous chorioretinopathy. Lee TG; Kim JE Br J Ophthalmol; 2011 Apr; 95(4):518-23. PubMed ID: 20679080 [TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy. Tseng CC; Chen SN Br J Ophthalmol; 2015 Aug; 99(8):1070-7. PubMed ID: 25680621 [TBL] [Abstract][Full Text] [Related]
14. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Cheng CK; Chang CK; Peng CH Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374 [TBL] [Abstract][Full Text] [Related]
15. Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy. Shinojima A; Kawamura A; Mori R; Fujita K; Yuzawa M Retina; 2011 Oct; 31(9):1912-20. PubMed ID: 21952105 [TBL] [Abstract][Full Text] [Related]
16. A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial. Zhao M; Zhang F; Chen Y; Dai H; Qu J; Dong C; Kang X; Liu Y; Yang L; Li Y; Zhou P; Pan CT; Zhang L; Liu P; Zhou H; Jiao X; Xiong Y; Tian R; Lu Y; Yu X; Li X JAMA Ophthalmol; 2015 Mar; 133(3):333-40. PubMed ID: 25555191 [TBL] [Abstract][Full Text] [Related]
17. [Photodynamic therapy for chronic central serous chorioretinopathy and diffuse retinal epitheliopathy]. Cornut PL; Quaranta-El Maftouhi M; Mauget-Faÿsse M J Fr Ophtalmol; 2012 Feb; 35(2):82-7. PubMed ID: 21889817 [TBL] [Abstract][Full Text] [Related]
18. Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group. Roca JA; Wu L; Fromow-Guerra J; Rodríguez FJ; Berrocal MH; Rojas S; Lima LH; Gallego-Pinazo R; Chhablani J; Arevalo JF; Lozano-Rechy D; Serrano M Br J Ophthalmol; 2018 Dec; 102(12):1696-1700. PubMed ID: 29439089 [TBL] [Abstract][Full Text] [Related]
19. Retinal sensitivity after photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: short-term results. Fujita K; Yuzawa M; Mori R Retina; 2011 Apr; 31(4):772-8. PubMed ID: 20890236 [TBL] [Abstract][Full Text] [Related]